MOMareki Ohtsuji

Mareki Ohtsuji

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mareki Ohtsuji has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Hematoxylin Dye Connecting Traditional Dyeing and Modern Medicine: Cultural History and Scientific Significance of Hematoxylin Staining

    by Mareki Ohtsuji, Kurumi Hayashi

    ヘマトキシリン・エオジン(Hematoxylin and Eosin,H & E)染色は,病理診断および組織学的研究において標準的かつ不可欠な染色法であり,細胞核や細胞質の構造を明瞭に可視化できる。ヘマトキシリンはマメ科の植物であるアカミノキ由来の天然色素で,16世紀に中米で発見され,19世紀には顕微鏡観察用の染色材料として利用された。1860年代以降,組織染色への応用が進み,現在では臨床診断にも広く応用されている。さらに布地や革製品の染色にも応用され,日本では「京黒染め」などに活用されてきた。本稿ではヘマトキシリンの歴史的背景と染色法の発展を概説する。

  • Open Access

    Anti-CD11b antibody treatment suppresses the osteoclast generation, inflammatory cell infiltration, and autoantibody production in arthritis-prone FcγRIIB-deficient mice

    by Mareki Ohtsuji, Qingshun Lin, Hideki Okazaki, Kazuko Takahashi, Hirofumi Amano, Hideo Yagita, Hiroyuki Nishimura, Sachiko Hirose

    Previously we established an arthritis-prone FcγRIIB-deficient mouse strain (designated KO1). Anti-mouse CD11b mAb (5C6) has been reported to inhibit the recruitment of peripheral CD11b+ myelomonocytic cells from the blood to the inflammatory site. These cells include neutrophils and monocytes, both of which play important roles in the development of arthritis. Here we treated KO1 mice with 5C6 mAb in order to study its effect on arthritis development. To evaluate the disease-preventive effect of 5C6, 4-month-old preclinical KO1 mice were divided into three groups: the first treated with 5C6 for 6 months, the second treated with normal rat IgG for 6 months, as a control, and the third left untreated. Arthritis severity and immunological abnormalities were compared among the groups, along with transcriptional levels of several important arthritis-related factors in ankle joints, spleen, and peripheral blood cells. The 5C6 treatment ameliorated arthritis in KO1 mice, showing decreases in inflammatory cell infiltration and osteoclast formation. Analysis of transcriptional levels in ankle joints revealed that compared with the two control groups, the 5C6-treated group showed downregulated expression of RANK, RANKL, MCP-1, RANTES, TNFα, and IL-6, and at the same time showed significantly up-regulated expression of the decoy receptor for RANKL, i.e. osteoprotegerin. In addition, the disease suppression was associated with the lower serum levels of autoantibodies, and the decreased frequencies of activated B cells and plasma cells. The expression levels of B cell activation/differentiation-related cytokines were suppressed in spleen and peripheral leukocytes of the 5C6-treated mice. Intriguingly, while untreated KO1 mice spontaneously developed marked monocytosis, the 5C6-treated mice showed the significantly down-regulated frequency of monocytes. The outcome of 5C6 treatment was complex, in which the 5C6-mediated disease-preventive effect is likely due on one hand to the decrease in the recruitment of inflammatory cells and osteoclast precursor monocytes from the periphery into the joints, and on the other hand to the suppression of B cell activation/maturation and of autoantibody production via the suppression of B cell stimulating cytokine production. The lower levels of these cytokines may be the secondary effect of the lower frequency of monocytes, since monocytes/macrophages are the major producers of these cytokines.